Back

Efficacy and safety of under-dose non-vitamin K antagonist oral anticoagulant with atrial fibrillation undergoing PCI: Insights from a nationwide population-based cohort study

27 August 2023 (12:15 - 12:50)
Organised by: Logo
Congress Presentation Part of: Pharmacology in coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Giseul Youk

Busan (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Optimal antiplatelet therapy for patients after antiplatelet therapy-induced gastrointestinal bleeding: when to resume?
Professor R. Huang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI
Doctor L. Galera (Manila, PH)
Abstract Slides Video
Presentation thumbnail
Interplay among proton pump inhibitors, platelet reactivity and CYP2C19 genotyping in clopidogrel-treated patients after drug-eluting stent implantation
Assistant Professor J. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study
Professor L. Wolff Gowdak (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients
Associate Professor K. Trusinskis (Riga, LV)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology in coronary artery disease

The Event

Event poster

ESC Congress 2023

27 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources